NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances.
作者信息
Lee Dawn, Burns Darren, Wilson Ed
机构信息
PenTAG, University of Exeter Medical School, University of Exeter, St Luke's Campus, Exeter, EX1 2LU, UK.
Delta Hat, Long Eaton, UK.
出版信息
Pharmacoecon Open. 2024 Sep;8(5):645-649. doi: 10.1007/s41669-024-00490-x. Epub 2024 Apr 13.
Abstract
摘要
相似文献
1
NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances.英国国家卫生与临床优化研究所的路径试点项目：在困难情况下追求良好决策。
Pharmacoecon Open. 2024 Sep;8(5):645-649. doi: 10.1007/s41669-024-00490-x. Epub 2024 Apr 13.
2
Correction: NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances.更正：英国国家卫生与临床优化研究所的路径试点项目：在困难情况下追求良好决策。
Pharmacoecon Open. 2024 Sep;8(5):783. doi: 10.1007/s41669-024-00499-2.
3
Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.公正、透明与英国国家卫生与临床优化研究所指导原则
Health Care Anal. 2022 Jun;30(2):115-145. doi: 10.1007/s10728-021-00444-y. Epub 2021 Nov 8.
4
Some inconsistencies in NICE's consideration of social values.英国国家卫生与临床优化研究所（NICE）在社会价值观考量方面存在一些不一致之处。
Pharmacoeconomics. 2014 Nov;32(11):1043-53. doi: 10.1007/s40273-014-0204-4.
5
DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.NICE 技术评估框架的决策组成部分。
Int J Technol Assess Health Care. 2018 Jan;34(2):163-171. doi: 10.1017/S0266462318000090. Epub 2018 Apr 10.
6
Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis.通过 NICE 的单一技术评估途径评估罕见病技术的灵活性：主题分析。
J Comp Eff Res. 2023 Nov;12(11):e230093. doi: 10.57264/cer-2023-0093. Epub 2023 Sep 19.
7
NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.NICE 与公平？英国国家卫生与保健卓越研究所 1999-2018 年的卫生技术评估政策
Health Care Anal. 2020 Sep;28(3):193-227. doi: 10.1007/s10728-019-00381-x.
8
Financial interests of patient organisations contributing to technology assessment at England's National Institute for Health and Care Excellence: policy review.患者组织对英格兰国家卫生与保健优化研究所技术评估的财务利益贡献：政策回顾。
BMJ. 2019 Jan 16;364:k5300. doi: 10.1136/bmj.k5300.
9
NICE's Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests.NICE 的折扣审查：理性修订的清晰思路遇到了行业利益的障碍。
Pharmacoeconomics. 2021 Feb;39(2):139-146. doi: 10.1007/s40273-020-00990-8. Epub 2021 Jan 19.
10
Modifying NICE's Approach to Equity Weighting.修改 NICE 的公平加权方法。
Pharmacoeconomics. 2021 Feb;39(2):147-160. doi: 10.1007/s40273-020-00988-2. Epub 2021 Jan 31.
引用本文的文献
1
Cost-Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn's Disease.中重度克罗恩病治疗方案的成本效用分析
Pharmacoeconomics. 2025 Aug 23. doi: 10.1007/s40273-025-01531-x.
2
A Cost-Effectiveness Analysis of Diffuse Large B-Cell Lymphoma Treatment Pathways in the United States.美国弥漫性大B细胞淋巴瘤治疗途径的成本效益分析
MDM Policy Pract. 2025 Jun 25;10(1):23814683251345780. doi: 10.1177/23814683251345780. eCollection 2025 Jan-Jun.
3
Comment on "Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria".关于《审查英国国家卫生与临床优化研究所单一技术评估的一致性：阵发性夜间血红蛋白尿评估综述》的评论
Pharmacoeconomics. 2025 Jul;43(7):835-837. doi: 10.1007/s40273-025-01500-4. Epub 2025 May 22.
4
Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria.审查英国国家卫生与临床优化研究所单一技术评估的一致性：阵发性夜间血红蛋白尿评估综述
Pharmacoeconomics. 2025 May;43(5):499-508. doi: 10.1007/s40273-025-01472-5. Epub 2025 Feb 12.
5
A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence.在治疗方法、价格和证据不断演变的背景下，利用成本效益分析支持新药品定价和报销决策的框架。
Pharmacoeconomics. 2025 Apr;43(4):363-373. doi: 10.1007/s40273-024-01450-3. Epub 2024 Dec 31.
本文引用的文献
1
R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study.用于成本效益分析的R语言和Shiny：为何以及何时使用？一个假设案例研究。
Pharmacoeconomics. 2020 Jul;38(7):765-776. doi: 10.1007/s40273-020-00903-9.
2
"Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.“时间旅行太危险了”，但有些方法值得重新审视：预期损失曲线相对于成本效益可接受性曲线和边界的优势。
Value Health. 2019 May;22(5):611-618. doi: 10.1016/j.jval.2019.02.008.
3
A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis.用于评估生物治疗类风湿关节炎价值的灵活开源决策模型。
Pharmacoeconomics. 2019 Jun;37(6):829-843. doi: 10.1007/s40273-018-00765-2.
4
Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.经济建模在英国国家卫生与临床优化研究所临床指南中的诊断和治疗路径：指南中的建模算法路径（MAPGuide）项目。
Health Technol Assess. 2013 Dec;17(58):v-vi, 1-192. doi: 10.3310/hta17580.
5
Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework.整体疾病建模以告知癌症资源分配决策：一种方法学框架。
Value Health. 2012 Dec;15(8):1127-36. doi: 10.1016/j.jval.2012.07.008. Epub 2012 Oct 25.
6
Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.呈现证据和总结措施，以在比较多种策略时为社会决策提供最佳信息。
Pharmacoeconomics. 2011 Jul;29(7):563-77. doi: 10.2165/11587100-000000000-00000.
7
The Mt. Hood challenge: cross-testing two diabetes simulation models.
Diabetes Res Clin Pract. 2000 Nov;50 Suppl 3:S57-64. doi: 10.1016/s0168-8227(00)00217-5.
Zotero 插件